A traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof

Abstract

The present application relates to the field of traditional Chinese medicine, in particular to a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof.The present application provides a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy, compared with the prescription of Chunzai Decoction, the traditional Chinese medicine composition of the present application increases the efficacy of promoting blood circulation and removing blood stasis, soothing the liver and relieving depression, clearing the liver and improving eyesight, clearing heat and reducing phlegm on the basis of Chunzai Decoction warming yang, transforming qi, reducing water and removing dampness;Compared with using Chunzai Decoction alone, the curative effect of patients using the traditional Chinese medicine composition is more direct, from 2-3 weeks to 1 week, and the curative effect is accelerated.And the traditional Chinese medicine composition of the present application has been used for about 2 years, 2 / 3 of the 112 patients can see effect in 1 week, and no recurrence is found within 3 months.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof. BACKGROUND

[0002] Central serous chorioretinopathy (CSC, for short, central serous) is the fourth most common chorioretinal disease, characterized by idiopathic serous retinal detachment (SRD) and retinal pigment epithelial detachment (PED), usually leading to central visual loss, metamorphopsia and metamorphosis, mainly affecting men aged 20-60 years. According to the duration of subretinal fluid and visual symptoms, CSC can be divided into acute (course ≤ 3 months) and chronic (course > 3 months). At present, the pathogenesis of the disease is not completely clear, but it may be related to increased choroidal permeability, increased hydrostatic pressure and damaged retinal pigment epithelial (RPE) outer barrier function. With the change of modern lifestyle and the increase of work pressure, the incidence of CSC has shown an upward trend in recent years. Although the disease has certain self-limiting nature, it is easy to relapse, and many cases are prolonged and unhealed, eventually causing irreversible damage to visual function, and in the later stage, macular atrophy or secondary choroidal neovascularization (CNV) can occur.

[0003] So far, there is no consensus on the treatment of CSC among experts in fundus diseases, and there is still a lack of standardized treatment programs or gold standard treatment methods in clinical practice. At present, the treatment of CSC in Western medicine mainly includes laser photocoagulation, photodynamic therapy (PDT), micro-pulse laser, anti-vascular endothelial growth factor (anti-VEGF) therapy and oral systemic drug therapy (spironolactone, eplerenone, melatonin or mifepristone, etc.). The treatment of CSC still faces some practical problems: ① Laser treatment is generally suitable for CSC with leakage points outside the fovea, which may cause contrast sensitivity decline, retinal scar, central scotoma and secondary CNV, and is not suitable for cases with leakage under or around the fovea; ② There is a lack of photosensitizer "Verteporfin" for PDT treatment, and PDT therapy may also have some adverse effects, including RPE atrophy, reduction of choroidal capillary layer perfusion, choroidal infarction and secondary CNV; ③ Micro-pulse laser has few side effects, but its efficacy is limited compared with PDT, and it has not been widely used; ④ Anti-VEGF therapy requires multiple injections, is invasive and expensive, and currently shows good efficacy in the case of chronic CSC secondary CNV, but the exact role of this drug in CSC is still unclear; ⑤ There is no sufficient evidence-based medical evidence to prove that the above oral systemic drugs can effectively treat CSC, and further prospective, multicenter, large sample size controlled studies are needed. In addition, in clinical work, some patients are very resistant to laser therapy or intraocular injection of anti-VEGF drug therapy, and some patients still have recurrence after treatment. In summary, the market demand for the treatment of CSC is huge, and the existing Western medicine treatment methods cannot meet the needs of the majority of patients. Therefore, carrying out clinical research on the treatment of CSC with traditional Chinese medicine has very important clinical application prospects and market potential. SUMMARY

[0004] The object of the present application is to provide a traditional Chinese medicine composition for treating central serous chorioretinopathy and its application, in order to solve the problems existing in the prior art. The composition of the present application can effectively treat central serous chorioretinopathy.

[0005] To achieve the above object, the present application provides the following solutions:

[0006] The present application provides a traditional Chinese medicine composition for treating central serous chorioretinopathy, which comprises the following components by mass:

[0007] Radix Astragali 15-45 parts, Tuckahoe 15-45 parts, Ramulus Cinnamomi 3-6 parts, Radix Bupleuri 3-10 parts, Fried Radix Scophulariae 15-30 parts, Radix Paeoniae Alba 10-30 parts, Rhizoma Chuanxiong 6-12 parts, Radix Rehmanniae 10-30 parts, Radix Lablab 15-30 parts, Fried Semen Plantaginis 15-30 parts, Radix Angelicae Sinensis 6-10 parts, Adzuki Bean 15-30 parts, Radix Alpiniae 15-30 parts and Radix Glycyrrhizae 3-6 parts.

[0008] Preferably, the traditional Chinese medicine composition comprises the following components in the mass parts:

[0009] Radix Astragali 15 parts, Tuckahoe 45 parts, Ramulus Cinnamomi 3 parts, Radix Bupleuri 8 parts, Fried Radix Scophulariae 20 parts, Radix Paeoniae Alba 30 parts, Rhizoma Chuanxiong 6 parts, Radix Rehmanniae 20 parts, Radix Lablab 15 parts, Fried Semen Plantaginis 20 parts, Radix Angelicae Sinensis 8 parts, Adzuki Bean 25 parts, Radix Alpiniae 25 parts and Radix Glycyrrhizae 6 parts;

[0010] or Radix Astragali 25 parts, Tuckahoe 30 parts, Ramulus Cinnamomi 4 parts, Radix Bupleuri 10 parts, Fried Radix Scophulariae 30 parts, Radix Paeoniae Alba 20 parts, Rhizoma Chuanxiong 7 parts, Radix Rehmanniae 30 parts, Radix Lablab 27 parts, Fried Semen Plantaginis 30 parts, Radix Angelicae Sinensis 6 parts, Adzuki Bean 30 parts, Radix Alpiniae 15 parts and Radix Glycyrrhizae 5 parts;

[0011] or Radix Astragali 45 parts, Tuckahoe 15 parts, Ramulus Cinnamomi 6 parts, Radix Bupleuri 3 parts, Fried Radix Scophulariae 15 parts, Radix Paeoniae Alba 10 parts, Rhizoma Chuanxiong 12 parts, Radix Rehmanniae 10 parts, Radix Lablab 30 parts, Fried Semen Plantaginis 15 parts, Radix Angelicae Sinensis 10 parts, Adzuki Bean 15 parts, Radix Alpiniae 30 parts and Radix Glycyrrhizae 3 parts.

[0012] The application provides application of the traditional Chinese medicine composition in preparation of a medicine for treating central serous chorioretinopathy.

[0013] The application provides a medicine for treating central serous chorioretinopathy, and preparation raw materials of the medicine comprise the traditional Chinese medicine composition.

[0014] Preferably, the medicine further comprises a pharmaceutically acceptable adjuvant.

[0015] Preferably, the medicine is in the form of decoction, pill, capsule, tablet, powder or granule.

[0016] The application provides a preparation method of the medicine, comprising the following steps:

[0017] Radix Astragali, Tuckahoe, Ramulus Cinnamomi, Radix Bupleuri, Fried Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Radix Lablab, Fried Semen Plantaginis, Radix Angelicae Sinensis, Adzuki Bean and Radix Alpiniae are mixed, and then water decocting is conducted to obtain the medicine.

[0018] Preferably, the water decocting is conducted at 100 DEG C for 20-30 min.

[0019] Preferably, the amount of water used in decocting is 5-10 times the total mass of the Astragali Radix, Poria, Ramulus Cinnamomi, Bupleuri Radix, Scutellariae Radix, Radix Paeoniae Alba, Chuanxiong Rhizoma, Radix Rehmanniae, Lablab Seed, Fructus Plantaginis, Angelica sinensis, and Coicis Semen.

[0020] The present application discloses the following technical effects:

[0021] The traditional Chinese medicine composition of the present application uses Astragali Radix as the monarch drug, which tonifies qi and raises yang, and promotes water excretion and reduces swelling. Poria, Lablab Seed, Coicis Semen, and Radix Paeoniae Alba serve as the minister drugs, which promote water excretion and dampness, and benefit qi and invigorate the spleen. Ramulus Cinnamomi, Bupleuri Radix, Scutellariae Radix, and Fructus Plantaginis serve as the auxiliary drugs, Ramulus Cinnamomi promotes water excretion and disperses qi, Bupleuri Radix raises yang qi, Scutellariae Radix clears heat and dries dampness, and Fructus Plantaginis clears heat and reduces phlegm. Radix Paeoniae Alba, Chuanxiong Rhizoma, Angelica sinensis, and Radix Rehmanniae form Siwu Decoction, which soothes the liver and invigorates the spleen, and resolves stasis and reduces fluid retention. Gansu Yiqi, which invigorates the spleen and benefits qi, adjusts the various drugs. The above drugs together raise qi and yang, resolve stasis and reduce fluid retention.

[0022] The Chunze Decoction is composed of Ramulus Cinnamomi, Atractylodes Macrocephala Koidz, Poria, Polyporus, Alisma Orientalis (Sam.) Juzep, and Panax ginseng, and mainly consists of traditional Chinese medicines that warm yang, transform qi, promote water excretion, and remove dampness. Compared with the composition of the Chunze Decoction, the traditional Chinese medicine composition of the present application adds the functions of promoting blood circulation and resolving stasis, soothing the liver and relieving depression, clearing the liver and improving eyesight, and clearing heat and reducing phlegm on the basis of warming yang, transforming qi, promoting water excretion, and removing dampness. Considering that the central serous chorioretinopathy is an eye disease, the traditional Chinese medicine composition of the present application adds traditional Chinese medicines that clear the liver and improve eyesight on the basis of promoting water excretion and removing dampness. The main pathogenesis of such patients is that the spleen fails to transport, and water and dampness are upward, which is considered to be phlegm and fluid retention in the Chinese medicine. Therefore, the traditional Chinese medicine composition of the present application strengthens water excretion and dampness removal, and adds traditional Chinese medicines that clear heat and reduce phlegm. In addition, the patients often suffer from the central serous chorioretinopathy due to excessive worry, emotional obstruction, fatigue, insomnia, and other emotional causes. Therefore, the traditional Chinese medicine composition of the present application adds traditional Chinese medicines that soothe the liver and relieve depression. It can be seen that the traditional Chinese medicine composition of the present application is more suitable for treating patients with central serous chorioretinopathy. Moreover, the traditional Chinese medicine composition of the present application has been used for about 2 years, and 2 / 3 of the 112 patients have seen effects in 1 week, and no recurrence has been found within 3 months. Compared with the Chunze Decoction alone, the traditional Chinese medicine composition of the present application has a more direct effect on the patients, and the time for seeing effects is accelerated from 2-3 weeks to 1 week.

[0023] Meanwhile, the medicine of the present application provides a new treatment option for patients, improves the efficacy of the disease, reduces the impact of the disease on the life of the patients, and has a small risk, small trauma, and light economic burden compared with the treatment method of western medicine for the central serous chorioretinopathy. DETAILED DESCRIPTION

[0024] The present application will now be described in detail with reference to a number of exemplary embodiments thereof, which should not be considered as limiting the application, but rather as being illustrative thereof, and as providing a more detailed description of certain aspects, features and embodiments of the application.

[0025] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the present application. In addition, where a range of values is provided, it is understood that each intervening value, to the upper and lower limit of the range is also specifically disclosed. Each smaller range between any stated value or intervening value in the stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of these smaller ranges can independently be included or excluded in the range.

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application. All documents mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the documents are cited. In case of conflict, the present specification will control.

[0027] Various modifications and changes can be made to the specific embodiments of the present application described herein without departing from the scope or spirit of the application. Other embodiments of the application will be apparent to those of ordinary skill in the art from the description and examples presented herein. The description and examples are illustrative only.

[0028] With respect to the use of "comprising", "including", "containing", "having" and "ensing" and the like, these terms are used in the sense of "open ended" and are intended to mean including but not limited to.

[0029] Example 1

[0030] Radix Astragali 45g, Poria 15g, Ramulus Cinnamomi 6g, Radix Bupleuri 3g, Radix Scophulariae 15g, Radix Paeoniae Alba 10g, Rhizoma Chuanxiong 12g, Radix Rehmanniae 10g, Dolichos 30g, Fructus Cheqianzi 15g, Radix Angelicae Sinensis 10g, Adzuki Bean 15g, Coix 30g, and Radix Glycyrrhizae 3g;

[0031] The preparation method of the medicine (Qiling mixture) for treating central serous chorioretinopathy comprises the following steps: mixing Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Dolichos, Fructus Cheqianzi, Radix Angelicae Sinensis, Adzuki Bean and Coix, and then decocting to obtain the medicine, wherein the decocting temperature is 100℃, and the decocting time is 30 min; during the decocting, the water amount is 5 times of the total mass of Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Dolichos, Fructus Cheqianzi, Radix Angelicae Sinensis, Adzuki Bean and Coix.

[0032] Example 2

[0033] Radix Astragali 15g, Poria 45g, Ramulus Cinnamomi 3g, Radix Bupleuri 8g, Fried Radix Scophulariae 20g, Radix Paeoniae Alba 30g, Rhizoma Chuanxiong 6g, Radix Rehmanniae 20g, Radix Labiati 15g, Fried Semen Plantaginis 20g, Radix Angelicae Sinensis 8g, Red Bean 25g, Radix Alpiniae 25g and Radix Glycyrrhizae 6g;

[0034] The preparation method of the medicine (Qiling mixture) for treating central serous chorioretinopathy comprises the following steps: mixing Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Fried Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Radix Labiati, Fried Semen Plantaginis, Radix Angelicae Sinensis, Red Bean and Radix Alpiniae, and then water decocting to obtain the medicine, wherein the water decocting temperature is 100℃, and the water decocting time is 20min; when water decocting, the water amount is 7 times of the total mass of Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Fried Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Radix Labiati, Fried Semen Plantaginis, Radix Angelicae Sinensis, Red Bean and Radix Alpiniae.

[0035] Example 3

[0036] Radix Astragali 25g, Poria 30g, Ramulus Cinnamomi 4g, Radix Bupleuri 10g, Fried Radix Scophulariae 30g, Radix Paeoniae Alba 20g, Rhizoma Chuanxiong 7g, Radix Rehmanniae 30g, Radix Labiati 27g, Fried Semen Plantaginis 30g, Radix Angelicae Sinensis 6g, Red Bean 30g, Radix Alpiniae 15g and Radix Glycyrrhizae 5g;

[0037] The preparation method of the medicine (Qiling mixture) for treating central serous chorioretinopathy comprises the following steps: mixing Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Fried Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Radix Labiati, Fried Semen Plantaginis, Radix Angelicae Sinensis, Red Bean and Radix Alpiniae, and then water decocting to obtain the medicine, wherein the water decocting temperature is 100℃, and the water decocting time is 25min; when water decocting, the water amount is 10 times of the total mass of Radix Astragali, Poria, Ramulus Cinnamomi, Radix Bupleuri, Fried Radix Scophulariae, Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Rehmanniae, Radix Labiati, Fried Semen Plantaginis, Radix Angelicae Sinensis, Red Bean and Radix Alpiniae.

[0038] Comparative Example 1

[0039] Xinzew Decoction is composed of 5g Ramulus Cinnamomi, 10g Rhizoma Atractylodis Macrocephalae, 10g Poria, 10g Polyporus, 15g Alisma, 7.5g Radix Ginseng, and the preparation method comprises the following steps: mixing Ramulus Cinnamomi, Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Alisma, Radix Ginseng, and then water decocting to obtain Xinzew Decoction, wherein the water decocting temperature is 100℃, and the water decocting time is 30min; when water decocting, the water amount is 7 times of the total mass of Ramulus Cinnamomi, Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Alisma and Radix Ginseng.

[0040] Experimental Example 1 Clinical experiment of central serous chorioretinopathy:

[0041] 1. Inclusion criteria of central serous chorioretinopathy:

[0042] The visual function changes mainly include:

[0043] Central vision: the central vision of the diseased eye suddenly decreased, if the original was emmetropia, the naked eye vision was generally not less than 0.5, the worst was not less than 0.2; often 0.50D-2.50D of temporary hyperopia appeared, which was explained as caused by the forward migration of macular retinal detachment;

[0044] Central scotoma: patients felt that the visual object of the affected eye was blurred, and there was a colored shadow in front of the eye, and the landscape was dim. Some patients also complained that there was a discoid shadow in the central visual field, and the central visual field could be found to be approximately corresponding to the size and formation of the posterior pole lesion. Fluorescence angiography showed that the macular area leaked, and some patients had obvious retinal reflection halo, macular edema, and central foveal light reflection was reduced or disappeared;

[0045] Micropia and metamorphopsia: compared with the healthy eye, the diseased eye had smaller or distorted visual objects, and straight lines became distorted.

[0046] Chest tightness, anorexia, vomiting, and loose stools;

[0047] Tongue fur is slippery and moist or stringy.

[0048] 2. Exclusion criteria: patients with mental disorders, chromosomal disorders, and organ function damage; lactating or pregnant women; patients with acute myocardial infarction.

[0049] 4. Central serous chorioretinopathy patients: 120 cases, aged 20-50 years, divided into 4 groups on average.

[0050] 5. Method of administration: oral administration 2 times a day, 10mL each time, for 1 month of treatment.

[0051] 6. Treatment effect

[0052] (1) Efficacy criteria

[0053] a. Cure: symptoms and signs disappeared, no recurrence after stopping;

[0054] b. Marked effect: symptoms and signs basically disappeared, and the recurrence was lighter after stopping;

[0055] c. Ineffective: no improvement after treatment.

[0056] (2) The results are shown in Table 1, wherein the calculation formula of the total effective rate is: total effective rate (%) = (cure + marked effect) / total cases x 100.

[0057] Table 1 Efficacy of different drugs

[0058] Group Example / Comparative Example Cured (human) Markedly effective (human) Ineffective (human) Total effective rate (%) 1 Example 1 26 3 1 96.67 2 Example 2 25 2 3 90 3 Example 3 27 1 2 93.33 4 Comparative Example 1 17 4 9 70

[0059] It can be known from Table 1 that the traditional Chinese medicine composition of the present application can effectively treat central serous chorioretinopathy, and the total effective rate can reach 96.67% at most. Moreover, it is found in the investigation that compared with the patients using the Chunze decoction in the prior art, the patients using the traditional Chinese medicine composition of the present application have more direct curative effect, and the effect is accelerated from 2-3 weeks to 1 week. It can be seen that the treatment effect of the composition of the present application is significantly improved.

[0060] Typical cases of experimental example 2

[0061] Case one: Lu, male, patient's left eye blurred vision for more than 3 months, accompanied by symptoms of dry eyes, swollen eyes, photophobia and wind tears. 11 years ago, the patient was treated with fundus photodynamic therapy in our hospital due to CSC in the right eye. The oral administration of western medicine had no obvious effect, and the patient took the prepared Qiling mixture of Example 1, 10 mL per time, 2 times per day. After 2 weeks of treatment, the left eye vision was obviously improved, and the OCT showed that the macular fovea edema was obviously subsided.

[0062] Case two: Zhang, male, patient's both eyes vision distortion with discoloration for 1 year. The patient was treated with fundus photodynamic therapy multiple times, but the symptoms recurred multiple times. The patient took the prepared Qiling mixture of Example 1, 10 mL per time, 2 times per day. After 1 month of treatment, the symptoms were basically subsided, and the OCT showed that the macular fovea edema was basically subsided. The patient was followed up for 1 year without recurrence.

[0063] Case three: Wang, male, patient's left eye vision blurred repeatedly for 2 years. The oral administration of western medicine had no obvious effect, and the patient took the prepared Qiling mixture of Example 2, 10 mL per time, 2 times per day. After 1 month of treatment, the symptoms were basically subsided, and the OCT showed that the macular fovea edema was basically subsided. The patient was followed up for 6 months without recurrence.

[0064] Case four: Shen, male, patient's right eye vision blurred repeatedly for 5 years. The patient was treated with anti-VEGF therapy in another hospital, but the symptoms recurred repeatedly, with an average of 3-6 months of recurrence. The patient took the prepared Qiling mixture of Example 3, 10 mL per time, 2 times per day. After 1 month of treatment, the symptoms were basically subsided, and the OCT showed that the macular fovea edema was basically subsided. The patient was followed up for 6 months without recurrence.

[0065] The above examples only describe the preferred modes of the present application, and do not limit the scope of the present application. Without departing from the design spirit of the present application, various modifications and improvements of the technical solutions of the present application made by those skilled in the art shall fall within the protection scope determined by the claims of the present application.

Claims

1. A traditional Chinese medicine composition for treating central serous chorioretinopathy, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Astragalus membranaceus 15-45 parts, Poria cocos 15-45 parts, Cinnamomum cassia 3-6 parts, Bupleurum chinense 3-10 parts, Scutellaria baicalensis (fried) 15-30 parts, Paeonia lactiflora (wheat bran) 10-30 parts, Ligusticum chuanxiong 6-12 parts, Rehmannia glutinosa (raw) 10-30 parts, Dolichos lablab 15-30 parts, Plantago asiatica (fried) 15-30 parts, Angelica sinensis 6-10 parts, Phaseolus angularis 15-30 parts, Coix lacryma-jobi 15-30 parts, and Glycyrrhiza uralensis 3-6 parts.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Astragalus membranaceus 15 parts, Poria cocos 45 parts, Cinnamomum cassia twig 3 parts, Bupleurum chinense 8 parts, stir-fried Scutellaria baicalensis 20 parts, whole wheat white peony root 30 parts, Ligusticum chuanxiong 6 parts, Rehmannia glutinosa 20 parts, white hyacinth bean 15 parts, stir-fried Plantago asiatica 20 parts, Angelica sinensis 8 parts, red adzuki bean 25 parts, Coix lacryma-jobi 25 parts, and Glycyrrhiza uralensis 6 parts; or Astragalus membranaceus 25 parts, Poria cocos 30 parts, Cinnamomum cassia twig 4 parts, Bupleurum chinense 10 parts, stir-fried Scutellaria baicalensis 30 parts, whole wheat white peony root 20 parts, Ligusticum chuanxiong 7 parts, Rehmannia glutinosa 30 parts, white hyacinth bean 27 parts, stir-fried Plantago asiatica 30 parts, Angelica sinensis 6 parts, red adzuki bean 30 parts, Coix lacryma-jobi 15 parts, and Glycyrrhiza uralensis 5 parts; Alternatively, the formula may consist of 45 parts Astragalus membranaceus, 15 parts Poria cocos, 6 parts Cinnamomum cassia, 3 parts Bupleurum chinense, 15 parts stir-fried Scutellaria baicalensis, 10 parts Paeonia lactiflora, 12 parts Ligusticum chuanxiong, 10 parts Rehmannia glutinosa, 30 parts Dolichos lablab, 15 parts stir-fried Plantago asiatica, 10 parts Angelica sinensis, 15 parts Phaseolus angularis, 30 parts Coix lacryma-jobi, and 3 parts Glycyrrhiza uralensis.

3. The use of the traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a drug for treating central serous chorioretinopathy.

4. A drug for treating central serous chorioretinopathy, characterized in that, The raw material for preparing the drug is the traditional Chinese medicine composition as described in claim 1 or 2.

5. The drug according to claim 4, characterized in that, The drug also includes pharmaceutically acceptable excipients.

6. The drug according to claim 5, characterized in that, The dosage form of the drug is decoction, pill, capsule, tablet, powder or granule.